Navigation Links
Heart failure: Intervention possibilities from imaging programmed cell loss

Using a nuclear medicine technique and molecular imaging to "see" programmed cell loss—the body's normal way of getting rid of unneeded or abnormal cells—may help in early identification of those individuals who are at risk of developing heart failure, say researchers in the April Journal of Nuclear Medicine.

"Our study indicates that it is feasible to noninvasively identify cell loss—or apoptosis—in heart failure patients using annexin A5 imaging," explained Leo Hofstra, director of cardiovascular imaging at the University Hospital of Maastricht in the Netherlands. "Such a strategy may offer a new possibility for studying interventions to minimize damage to the heart muscle," he added. "This research is significant since cell loss is potentially reversible and earlier intervention could delay the development of cardiomyopathy or heart muscle disease," noted Hofstra. He indicated that additional research is needed since the study was performed on a small group of heart patients.

"Heart failure is a major health care problem," said Hofstra, "and researchers are looking at novel ways to improve patient care." With heart failure, a person's heart no longer pumps sufficient blood to the body's organs. Nearly 5 million Americans are living with heart failure—a long-term condition that tends to gradually worsen—and 550,000 new cases are diagnosed each year.

Researchers attached a radioactive substance to annexin A5, a protein that binds to dying cells, said Hofstra. They then used nuclear imaging that produces three-dimensional computer-reconstructed images to reveal information about both structure and function to measure the amount of annexin A5 absorbed. Annexin A5 bound to the damaged heart muscle. "We discovered that higher uptake was uptake with a worse outcome. Cell death is one of the biological events that worsens left ventricular events," said Hofstra.

"Our results indicate that heart muscle cell death is an active and ongo ing process in heart failure, and that annexin imaging could possibly guide treatment for heart patients and be used to determine whether a treatment was working," said Hofstra, co-author of "Noninvasive Detection of Programmed Cell Loss with 99mTc-Labeled Annexin A5 in Heart Failure." He anticipates that this research would spur development of new drugs for heart disease.


'"/>

Source:Society of Nuclear Medicine


Related biology news :

1. HIV Patients May Be at Risk of Heart Problems When Taking Protease Inhibitor Drugs
2. Implanted Devices Detect High-Risk Heart Failure Patients
3. Rush Physicians Using Gene Therapy For Heart Patients With Moderate To Severe Chest Pains Who Do Not Benefit From Other Treatments
4. Special Imaging Study Shows Failing Hearts Are Energy Starved
5. Stem Cell Research Shows Potential for Replacing Tissue Damaged in Heart Attacks
6. Heart repair gets new muscle
7. Male Combat Veterans Rank High In Heart Disease Risk
8. Newly Discovered Role for Heart Response Enzyme May Yield Better Heart Failure Therapy
9. Researchers Find Drug May Give Some Cardiac Protection 24 Hours After Heart Attack
10. Heart-healthy compound in chocolate identified
11. Heart has enough oxygen to survive hypothermia, CPR crucial
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/19/2017)... , Jan. 19, 2017 ... user experience and security for consumer electronics, and ... payment processing systems and cybersecurity solutions, today announced ... enterprises and financial institutions worldwide to bolster security ... the end-to-end secure user authentication platforms they offer, ...
(Date:1/18/2017)... 2017 MedNet Solutions , an ... entire spectrum of clinical research, is proud to ... for the organization in terms of corporate growth, ... products and services. The company,s exceptional achievements can ... iMedNet ™ – ...
(Date:1/12/2017)... 12, 2017  Trovagene, Inc. (NASDAQ: TROV ... today announced that it has signed agreements with seven ... the Middle East for commercialization ... the first wave of international distribution agreements for Trovagene,s ... samples. The initial partners will introduce Trovagene,s ...
Breaking Biology News(10 mins):
(Date:2/18/2017)... Arlington Heights, IL (PRWEB) , ... February 17, ... ... Society for Blood and Marrow Transplantation (ASBMT) and the Center for International Blood ... Gaylord Palms Convention Center in Orlando, Fla. , The combined scientific ...
(Date:2/17/2017)... , Feb. 17, 2017  BioGenex, a global ... development of a novel system for quantitative immunohistochemistry ... the University of Rochester (NY, USA) and Konica-Minolta ... new system is able to accurately quantify the ... (Human epidermal growth factor receptor-2) in clinical samples. ...
(Date:2/16/2017)... ... February 16, 2017 , ... EIT Digital has launched work to ... industry. Pilot studies are about to get under way for the framework, which is ... innovations. The concept is expected to be transferred eventually to other industries that also ...
(Date:2/16/2017)... 16, 2017  MDNA Life Sciences Inc. (MDNA), ... liquid biopsy tests based on the mitochondrial genome, ... license agreement with its first international commercial partner, ... test for prostate cancer, the Prostate Mitomic Test ... This is the first overseas appointment for MDNA ...
Breaking Biology Technology: